Sugi Predict

Sugi Predict / Compounds / SCHEMBL1633846

SCHEMBL1633846

SCHEMBL1633846

Clc1ncc2ccc(Br)cc2n1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ BACE1 P56817 2/20 0.47
▸ KDM4E B2RXH2 2/20 0.46
▸ ALDH1A1 P00352 2/20 0.46
▸ SMN1; SMN2 Q16637 1/20 0.46
▸ HTT P42858 2/20 0.46
▸ CYP1A2 P05177 1/20 0.46
▸ CYP2C19 P33261 1/20 0.46
▸ EGFR P00533 1/20 0.39
▸ NOS1 P29475 2/20 0.37
▸ METAP2 P50579 2/20 0.37
▸ DYRK1A Q13627 1/20 0.37
▸ PABPC1 P11940 1/20 0.36
▸ NPM1 P06748 1/20 0.36
▸ ALK Q9UM73 1/20 0.36
▸ CYP2A6 P11509 1/20 0.35
▸ NT5E P21589 1/20 0.35
▸ PTGES O14684 2/20 0.35
▸ GSK3A P49840 1/20 0.34
▸ CDK9 P50750 1/20 0.34
▸ CDK5 Q00535 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29516187 1.00 BACE1 (0.47) BACE1KDM4EALDH1A1SMN1; SMN2HTT
SCHEMBL1570789 0.84 HTT (0.49) BACE1KDM4EALDH1A1SMN1; SMN2HTT
SCHEMBL31271736 0.76 BACE1 (0.47) BACE1ALDH1A1SMN1; SMN2HTTCYP1A2
SCHEMBL558609 0.76 KDM4E (0.46) BACE1KDM4EALDH1A1SMN1; SMN2CYP1A2
SCHEMBL30380023 0.76 BACE1 (0.57) BACE1KDM4EALDH1A1HTTCYP1A2
SCHEMBL30908162 0.76 ALDH1A1 (0.50) BACE1KDM4EALDH1A1SMN1; SMN2CYP1A2
SCHEMBL1741867 0.76 BACE1 (0.57) BACE1KDM4EALDH1A1HTTCYP1A2
SCHEMBL1632488 0.76 BACE1 (0.47) BACE1KDM4EALDH1A1HTTCYP1A2
SCHEMBL4297504 0.76 BACE1 (0.47) BACE1KDM4EALDH1A1HTTCYP1A2
SCHEMBL6833410 0.76 BACE1 (0.47) BACE1ALDH1A1SMN1; SMN2HTTCYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-121248582-B CDK12/PARP double-target inhibitor and preparation method and application thereof SOUTH CHINA UNIVERSITY OF TECHNOLOGY (CN) 2026-05-26 — — CN disclosed
US-20260132122-A1 6-6-FUSED BICYCLIC HETEROARYL AMINES AS CDK4 INHIBITORS INCYTE CORP (US) 2026-05-14 — — US disclosed
EP-4211119-B1 2-AMINOQUINAZOLINES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF MERCK SHARP & DOHME LLC (US) 2026-05-13 — — EP disclosed
EP-4739306-A2 POLO-LIKE KINASE 1 INHIBITORS Cervero Therapeutics, LLC (US) 2026-05-13 — — EP disclosed
US-12612424-B2 HPK1 inhibitors and uses thereof REGOR PHARMACEUTICALS, INC. (US) 2026-04-28 — — US disclosed
US-12570640-B2 2-aminoquinazolines as LRRK2 inhibitors, pharmaceutical compositions, and uses thereof MERCK SHARP & DOHME LLC (US) 2026-03-10 — — US disclosed
EP-4568954-A1 INHIBITORS OF CYCLIN-DEPENDENT KINASE (CDK) 12 AND/OR CDK13 AND USES THEREOF Insilico Medicine IP Limited (HK) 2025-06-18 — — EP disclosed
CN-119677729-A Cyclin Dependent Kinase (CDK) 12 and/or CDK13 inhibitors and uses thereof 英矽智能科技知识产权有限公司 2025-03-21 — — CN disclosed
CN-119661537-A Nucleoside compound, preparation method thereof, composition thereof and application of nucleoside compound in medicine 中国科学院上海药物研究所 2025-03-21 — — CN disclosed
WO-2025046148-A1 NOVEL PARG INHIBITORS FORX THERAPEUTICS AG (CH) 2025-03-06 — — WO disclosed
US-7932262-B2 Quinazolines for PDK1 inhibition NOVARTIS AG (CH) 2011-04-26 — — US disclosed
US-7932262-B2 Quinazolines for PDK1 inhibition NOVARTIS AG (CH) 2011-04-26 — — US disclosed
US-7932262-B2 Quinazolines for PDK1 inhibition NOVARTIS AG (CH) 2011-04-26 — — US disclosed
US-20100048561-A1 QUINAZOLINES FOR PDK1 INHIBITION NOVARTIS VACCINES & DIAGNOSTICS, INC. (US) 2010-02-25 — — US disclosed
US-20100048561-A1 QUINAZOLINES FOR PDK1 INHIBITION NOVARTIS VACCINES & DIAGNOSTICS, INC. (US) 2010-02-25 — — US disclosed
US-20100048561-A1 QUINAZOLINES FOR PDK1 INHIBITION NOVARTIS VACCINES & DIAGNOSTICS, INC. (US) 2010-02-25 — — US disclosed
CN-101454294-A Quinazolines for pdk1 inhibition NOVARTIS AG (CH) 2009-06-10 — — CN disclosed
EP-2004615-A2 QUINAZOLINES FOR PDK1 INHIBITION Novartis AG (CH) 2008-12-24 — — EP disclosed
WO-2007117607-A9 QUINAZOLINES FOR PDK1 INHIBITION NOVARTIS VACCINES & DIAGNOSTIC (US) 2008-03-06 — — WO disclosed
WO-2007117607-A2 QUINAZOLINES FOR PDK1 INHIBITION NOVARTIS AG (CH) 2007-10-18 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12612424-B2 HPK1 inhibitors and uses thereof NEK11, NEK1, CSNK1A1 BACE1 3984/4885KDM4E 2717/4885ALDH1A1 3619/4885
US-12570640-B2 2-aminoquinazolines as LRRK2 inhibitors, pharmaceutical compositions, and uses thereof LRRK2, PARK7, CLK2 BACE1 1612/4885KDM4E 2711/4885ALDH1A1 3924/4885
US-20260132122-A1 6-6-FUSED BICYCLIC HETEROARYL AMINES AS CDK4 INHIBITORS CCNA1, CDK4, CCNO BACE1 3678/4885KDM4E 2159/4885ALDH1A1 995/4885
US-20100048561-A1 QUINAZOLINES FOR PDK1 INHIBITION PDK1, PDK2, PDK3 BACE1 3953/4885KDM4E 1007/4885ALDH1A1 2679/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.